Pfizer and Moderna Enter the Oncology Drug Market: Billions at Stake in Treating Turbo-Cancers Post-mRNA Vaccination

Pfizer has astonished the medical world by finalizing a $43 billion acquisition of Seagen, a small pharmaceutical company treating turbo cancers and barely making $2 billion annually, as reported by THAI MBC.

The acquisition means Pfizer becomes the largest oncology company globally, capable of treating most turbo cancers caused by mRNA vaccines.

However, the nature of the acquisition has left many scratching their heads. Why would Pfizer, already endowed with massive profits from its mRNA vaccine, pay an additional $43 billion for a small cancer drug company?

According to the cited source, Pfizer will borrow $31 billion to buy Seagen. Everyone is taking this at face value, but there’s something very sinister hiding in the details of this transaction.

Firstly, we must acknowledge that Pfizer’s COVID-19 mRNA vaccines (as well as Moderna’s) cause turbo cancers at unprecedented rates in world history. Recently, Moderna announced it developed the first mRNA vaccine for treating cancers.

Based on case descriptions of turbo-cancers from over 30 medical articles, here are the top 5 turbo-cancers observed, in terms of frequency, in individuals vaccinated with at least one dose of mRNA:

Lymphoma (various types) Brain cancers (especially glioblastoma) Breast cancer (mostly triple-negative, stage 3/4) Colon cancer (stage 4) Lung cancer (stage 4) Leukemias (the worst prognosis) Melanomas (stage 4) Sarcomas (stage 3, 4) Testicular/ovarian (rapid progression, stage 1-4) Kidney (stage 4 RCC)

Through the new acquisition, Pfizer has gone from being able to “treat” two of these turbo-cancer types to being capable of treating seven out of ten. Not bad for a company seeking to monopolize the market in treating the same issues it causes.

But it gets worse. Pfizer’s CEO, Albert Bourla, embarked on a media interview tour about the $43 billion Seagen acquisition. Here are the key takeaways from his interviews:

• 33% of people WILL get turbo cancer in the future (he’s certain of this)
• Entire families WILL be affected (again, he’s sure)
• New cancer treatments are like “rockets” targeting “most” turbo-cancers
• Pfizer will produce them on an unprecedented scale
• By 2025, Pfizer will “have a global footprint”
• “We have a very rapid way of finalizing clinical studies”
• They will be produced “at scale,” “just like mRNA.”

Seeking Alpha’s analysis theorizes that Pfizer will need at least a decade just to recover from this deal. Financially, this $43 billion acquisition doesn’t make sense for Pfizer, unless Bourla and his cohorts know something about the future and aren’t telling us.